Please assess the completion status of the following clinical trial:

Trial Title: Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Prostate cancer proven by histopathology~2. Unresectable metastases~3. Progressive disease, both docetaxel naive and docetaxel treated.~4. Castration resistant disease with confirmed testosterone level ≤50 ng/ml under prior androgen deprivation therapy (ADT)~5. Positive 68Ga-PSMA-11 PET/CT (positron emission computed tomography ) or diagnostic 177Lu-PSMA-617 scintigraphy~6. ECOG 0-2~7. Sufficient bone marrow capacity as defined by WBC (white blood cell ) ≥2.500/μl, PLT (platelet) count ≥100.000/μl, Hb≥9.9 g/dl and ANC≥1500 mm3 for the first cycle and WBC≥2.000/ μl,PLT count ≥75.000/μl, Hb≥8.9 g/dl and ANC≥1000 mm3 for the subsequent cycles~8. Signing of the Informed Consent Form~9. Patients enrolling in this trail should have received either Enzalutamide or Abiraterone~Exclusion Criteria:~1. Less than 6 weeks since last myelosuppressive therapy (including Docetaxel, Cabazitaxel, 223Ra, 153Sm) or other radionuclide therapy.~2. Glomerular Filtration Rate (GFR) \<40 ml/min~3. Serum creatinine \> 1.5 ULN~4. AST and ALT\>5xULN~5. Urinary tract obstruction or marked hydronephrosis~6. Diffuse bone marrow involvement confirmed by super-scans

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 177Lu-PSMA-617 (6.0 GBq) (Type: EXPERIMENTAL): Repeated i.v. application of 6.0 GBq (gigabequerel)(+/- 10%, arm 1) every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
- 177Lu-PSMA-617 (7.4 GBq) (Type: EXPERIMENTAL): Repeated i.v. application of 7.4 GBq (gigabequerel)(+/- 10%, arm 2) of drug every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry

Based on this trial design, predict the completion outcome and termination type (if applicable).